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Abstract
Renal medullary carcinoma (RMC) is a rare, highly aggressive tumor recognized as an independent pathological entity. African-descent 
adolescents and young adults with sickle cell hemoglobinopathy are the most affected groups. This rare subtype of renal cell carcinoma 
has its own morphogenetic and pathological characteristics. The major clinical manifestations include gross hematuria, abdominal or 
flank pain, and weight loss. The prognosis is very poor, with 95% of cases diagnosed at an advanced stage of the disease. In this review, 
we summarize the morphologic and dynamic characteristics of RMC under various imaging modalities such as ultrasound, computed 
tomography, and magnetic resonance. Differential diagnosis and management strategies are also discussed.
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Introduction
Renal medullary carcinoma (RMC) is a rare, highly aggres-
sive tumor considered an independent pathological entity 
(1, 2). Although African-descent adolescents and young 
adults with sickle cell (SC) hemoglobinopathies are the most 
affected, there are reports of RMC in non–African-American 
patients without hemoglobinopathy (1, 3). Men are affected 
more often than women (M:F = 2:1) (1, 3). Some authors con-
sider RMC to be a subtype of collecting duct carcinoma (4). 
Both tumors are derived from the renal medulla, biologically 
aggressive, and characterized by an infiltrative growth pat-
tern (1, 2). Regarding tumor genesis, a relationship between 
hypoxia and angiogenesis has been suggested (4). Hypoxia 
increases the expression of hypoxia-inducible factor (HIF). 
It determines tumor protein p53 production, which induces 
apoptosis. In tumors lacking p53, however, HIF induces 
vascular endothelial growth factor leading to angiogenesis, 
which is necessary for the progression of disease (5). This 
hypothesis would explain the relationship between RMC and 
SC trait (4). Also, an increase in the ABL gene amplification 
and inactivation of the tumor suppressor gene SMARCB1 
have been reported (6, 7).
This rare subtype of renal cell carcinoma (RCC) has its 
own morphogenetic and pathological features (8). The his-
tologic features include reticular or yolk sac growth pattern, 
varying degrees of mucin production, stromal desmoplasia, 
and inflammatory infiltrates with lymphocytes at the margins 
(4). Most RMCs have hemorrhagic and necrotic areas (1). 
The cells have large and clear vesicular nuclei,  prominent 
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nucleoli, and dark cytoplasm with variable amounts of 
 eosinophilic cytoplasm (9). There is frequently lymphatic 
and/or vascular invasion (1). Collecting duct carcinoma is 
characterized by cystic or papillary macroscopic appearance 
and tubular or papillary growth pattern. Furthermore, collect-
ing duct carcinoma is often found in adults and is not asso-
ciated with hemoglobinopathies (10). In 70% of cases, RMC 
is localized in the right kidney (11). The clinical presentation 
is characterized by gross hematuria, abdominal or flank pain, 
and loss of weight. The sites of metastases are locoregional 
lymph nodes, adrenal glands, liver, lungs, inferior vena cava, 
and the peritoneum (1, 12). The prognosis of RMC is very 
poor, and 95% of tumors are detected at an advanced stage. 
They are resistant to chemotherapy and biological therapy 
(13, 14). Simpson et al. (15) reported an average survival of 
19 weeks from the time of initial diagnosis of RMC. Radical 
nephrectomy in patients with carcinoma in situ seems to pro-
long the survival time (16). An early and accurate diagnosis 
is very important, as it may improve the prognosis of patients.
Herein, we describe the morphological and dynamic char-
acteristics of RMC under various diagnostic imaging tech-
niques. A PubMed search was performed for the following 
terms: “Renal medullary carcinoma,” “Renal medullary car-
cinoma ultrasound,” “Renal medullary carcinoma computed 
tomography,” and “Renal medullary carcinoma magnetic res-
onance imaging.” As RMC was considered a disease entity 
in 1995, the search was performed for literature published 
between 1995 and 2016.
Ultrasound Imaging of RMC
Accidental detection of renal lesions during abdominal ultra-
sound imaging is very common. About 35% of patients, in 
their seventh decade of life, have some form of a renal cyst 
(17). More than 50% of RCC are diagnosed by imaging, well 
before the appearance of clinical signs or symptoms (18, 19). 
Ultrasonographic features of RMC have been described by 
various authors. Khan et al. (11) described the sonographic 
characteristics of RMC in a 29-year-old man of Afro-Carib-
bean descent. The RMC was a 13-cm solid mass in the left 
renal pelvis with focal hydronephrosis of the upper and lower 
poles of the kidney. No evidence of lymphadenopathy was 
found at the ultrasound. Doppler study showed no flow in 
the renal mass. The application of power Doppler revealed 
minor peritumoral vascularity (11). Sathyamoorthy et al. (20) 
described an enlarged and diffusely echogenic right kidney, 
with an infiltrative mass located at the lower pole and vast 
lymphadenopathy, which was diagnosed as RMC. However, 
in other two studies, ultrasound failed to detect renal masses, 
and in one of these, the increased echogenicity of the medul-
lary areas of an enlarged right kidney was misinterpreted as 
papillary necrosis. Two days after the ultrasound examina-
tion, the tumor was detected on computed tomography (CT) 
(21, 22). In another case, the ultrasound examination was 
negative. Two months later, the patient was diagnosed with 
cancer with the help of CT (23).
In the past decade, contrast-enhanced ultrasound (CEUS) 
made progress, allowing the study of vascularization of the 
renal lesions even in patients with renal insufficiency. The 
European Federation of Societies for Ultrasound in Medi-
cine and Biology produced the protocols and guidelines for 
the use of CEUS to standardize this practice (24). Several 
studies have described the characteristics of renal lesions 
using CEUS; however, none of these studies has detected 
RMC. Tamai et al. (25), on histopathological examination 
of resected lesions conducted on 29 patients, diagnosed 26 
malignant lesions (18 clear cell carcinoma, 6 papillary RCCs, 
1 collecting duct carcinoma, and 1 infiltrative urothelial car-
cinoma) and 3 benign lesions (2 oncocytoma and 1 angio-
myolipoma). Ignee et al. (26) analyzed 137 renal lesions by 
CEUS. No RMC was detected. Gerst et al. (27), among 34 
patients studied with CEUS, diagnosed 23 clear cell carci-
nomas, 3 type 1 papillary carcinomas, 1 chromophobe carci-
noma, 1 clear multilocular rare low-grade malignant tumor, 
2 unclassified lesions, 3 oncocytomas, and 1 benign angio-
myolipoma. Yong et al. (28) analyzed 74 renal lesions of 63 
patients, diagnosing 22 malignant lesions. Ten of these lesions 
were confirmed on histology (six clear cell carcinomas, three 
papillary carcinomas, and one lesion showed spindle and epi-
thelioid cells, which could not exclude an angiomyolipoma). 
Thus, it appears that ultrasound imaging is insufficient for the 
diagnosis of RMC or medullary renal lesions.
CT Imaging of RMC
Several studies have evaluated RMC features at CT exami-
nation (Table 1) (2, 11, 20, 21, 29–32). The radiological fea-
tures of RMC were first reported in 1995 by Davidson et al. 
(2) in five black patients, aged between 10 and 28 years, 
with SC trait (SCT). All five patients had advanced stage 
disease at diagnosis. Modes of disease spread included local 
direct invasion (regional lymph nodes, renal vein and infe-
rior vena cava, liver, adrenal gland, and retroperitoneal soft 
tissue) and distant metastases (liver, lungs, omental lymph 
nodes, and pulmonary hilar lymph nodes). In all patients, 
the lesions were located within the renal parenchyma and 
involved the renal pelvis and sinus. The tumors showed an 
infiltrating pattern of growth; the kidneys were enlarged with 
the reniform aspect still preserved. The tumors surrounded 
and obstructed the pelvis; there was also clear caliectasis. A 
large area of necrosis and a heterogeneous contrast enhance-
ment was also visible. In three of the five patients, the tumor 
caused caliectasis without pelviectasis. In one patient, there 
was communication between the necrotic cavity and the col-
lecting system (2).
A recent study described the clinical and CT imaging fea-
tures of RMC in six patients (three women and three men; 
mean age, 50.5 years) (29). In three cases, the tumor was 
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localized in the right kidney, and in the other three in the 
left kidney. The size of the primary lesion was between 2.90 
and 10.50 cm (mean diameter, 7.48 ± 3.25 cm). In addition, 
three patients had hydronephrosis and caliectasis, and two 
had retroperitoneal lymph node metastases. SC hemoglobin-
opathy was present in one patient, and in the remaining five, 
the presence of SCT was unknown before the RMC detec-
tion. In all six cases, the tumor was in the medulla and infil-
trated the renal pelvis. In four cases, they extended to the 
renal cortex, and in only one case, they reached the perirenal 
tissue. The lesions were predominantly solid and heterogene-
ous, with necrotic or cystic components; microcalcifications 
were present in only one case. The margins were well defined 
in two cases and poorly defined in the other four cases. The 
fibrous capsule was not present in any patients. In the case 
where the tumor reached the retroperitoneal fat, the left renal 
artery was infiltrated and regional lymph node metastases 
were present. In all cases, the attenuation of RMC on unen-
hanced CT was equal to normal renal cortex and medulla. On 
dynamic contrast-enhanced CT scan, the RMC density was 
much lower than the density of the normal renal cortex and 
medulla during all three phases enhanced: arterial (cortical) 
phase, cortico-medullary (medullary), and excretory phase 
(delayed) (29). With regards to vascularization, two angio-
grams, describing two kinds of lesions have been reported: 
hypovascular and avascular, with few small ectatic vessels 
surrounding the tumor (2, 11).
Khan et al. (11) described the CT features of RMC in the 
case of a 29-year-old man of Afro-Caribbean descent with 
SCT. It was a solid mass in the left kidney, with hypodense 
area, presumably attributable to necrosis. Medially to the 
lesion, a portion of compressed healthy renal parenchyma 
was visible. The kidney showed a thickened and irregular 
renal capsule; the ipsilateral psoas muscle appeared thick-
ened. There were also some enlarged lymph nodes that moved 
medially and right to the aorta (11). A case of a 20-year-old 
African-American man showed an enlargement of the right 
kidney and a diffuse retroperitoneal lymphadenopathy on 
unenhanced CT scan (30). Dynamic contrast-enhanced CT 
scan confirmed the retroperitoneal lymphadenopathy and 
showed a diffuse enlargement with attenuation and hetero-
geneous enhancement of the kidney. Adjacent perinephric 
stranding and thickening of the renal fascias suggested 
an infiltrative process. Chest CT showed paratracheal and 
mediastinal lymphadenopathy and nodular ground-glass 
densities in the context of the lung parenchyma, suggesting 
a diagnostic hypothesis of lymphoma with renal involve-
ment (30). Another case of a 36-year-old African-American 
man with SC disease showed a heterogeneous infiltrative 
mass of the right kidney, with extensive retroperitoneal lym-
phadenopathy (31).
Blitman et al. (21) analyzed six patients with SCT (three 
men and three women; aged from 15 to 27 years). Four were 
black, and two were Hispanic. The tumors were located in the 
central portion of the right kidney. They were  hypovascular 
with ill-defined margins and infiltrative characteristics. Cali-
ectasis were also present. There were enlarged retroperitoneal 
lymphadenopathies in five patients, whereas necrosis was 
Table 1. CT features of RMC
References RK LK N C Calc H WM PM RL LiM LuM IH SH TA TV
Davidson  
et al. (2)
3 1 5 3 - - - - PNS PNS PNS - - - PNS
Khan et al. (11) - 1 1 1 - - - - 1 - - - - - -
Blitman et al. 
(21)
6 - 4 6 - - - 6 5 3 4 4 1 - 2
Baig et al. (31) 1 - 1 - - - - - 1 - - - - - -
Sathyamoorthy 
et al. (20)
1 - 1 - - - - - 1 - - - - - -
Neville et al. 
(30)
1 - - - - - - - 1 - 1 - - - -
Raman et al. 
(32)
3 - 3 - - - 1 1 2 - - - - - 1
Shi et al. (29) 3 3 6 3 1 3 2 4 2 - - - - 1 -
C, caliectasis; Calc, calcifications; H, hydronephrosis; IH, intratumoral hemorrhage; LiM, liver metastasis; LK, left kidney; LuM, lung metastasis; 
N, necrosis; PM, poorly defined margin; PNS, present but not specified; RK, right kidney; RL, retroperitoneal lymphadenopathy; SH, subcapsular 
hemorrhage; TA, thrombosis of the renal artery; TV, thrombosis of the renal vein; WM, well-defined margin.
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present in four cases. Intratumoral hemorrhage was demon-
strated in four patients, whereas subcapsular hemorrhage was 
present in one patient. Calcifications were absent. Thrombo-
sis of the right renal vein was present in two, and the vas-
cular pedicle was contained without signs of thrombosis in 
three of the six patients. With regard to distant metastasis, 
the presence of hepatic lesions was described in two patients, 
pulmonary lesions in three patients, liver and lung metastasis 
in one patient, and no metastasis in one patient at the time of 
diagnosis. The CT appearance of lung lesions was varying: 
small nodule (n = 1), cannonball lesion (n = 1) or a thick 
pleura-based rind (n = 1). In one case, the presence of infiltra-
tion of the renal vein was noticed during surgery, which was 
not noticed on the CT images (21).
In 2003, Sathyamoorthy et al. (20) reported a heterogene-
ous, large, infiltrating mass localized at the level of the lower 
pole of the right kidney, and a large retroperitoneal lymphad-
enopathy encasing the renal arteries, renal veins, aorta, and 
inferior vena cava. Three more cases were reported in 2012. 
A 10-year-old African-American boy had CT evidence of a 
hypodense, heterogeneous, large mass of the right kidney, 
infiltrating the right renal vein with a retroperitoneal lym-
phadenopathy and bone metastases. The characteristics of 
the lesion margins, in this case, have not been described. 
A 13-year-old African-American boy with SCT showed 
CT evidence of a hypodense mass of the right kidney with 
ill-defined margins and retroperitoneal, mediastinal, and 
supraclavicular lymphadenopathies. The patient, subjected 
to nephrectomy, developed bone metastases despite chemo-
therapy. In a 17-year-old adolescent boy with a history of 
SCT, the CT images showed a hypodense mass of the right 
kidney with well-defined margins. At the time of diagnosis, 
the patient had no metastatic lesions. After nephrectomy, he 
developed metastases to the liver, bone, and brain during 
chemotherapy (32).
Among all 24 patients, the most frequent CT features of 
RMC detected at diagnosis were necrosis of the lesion (21 
patients), location in the right kidney [18 patients; in the 
study by Davidson et al. (2), in one of the five patients, tumor 
location was not specified], retroperitoneal lymphadenopa-
thy [between 14 and 18 patients; Davidson et al. (2) did not 
specify how many patients among the five cases studied had 
the lymphadenopathies], caliectasis (13 patients), and poorly 
defined margins (11 patients). All the cases showed a lower 
frequency of lung metastases (five to nine patients), location 
in the left kidney (six patients), intratumoral hemorrhage 
(four patients), liver metastases (four to eight patients), and 
renal vein thrombosis (four to eight patients). More rare are 
well-defined margins (three patients), hydronephrosis (three 
patients), and subcapsular hemorrhage and calcifications 
(one patient) (2, 11, 20, 21, 29–32) (Table 1). In the above 
summary, necrosis and localization were evaluated by us both 
from the description and the images if they were not men-
tioned in the report.
Magnetic Resonance Imaging of RMC
Few studies have described the RMC features through the 
use of magnetic resonance imaging (MRI). Khan et al. (11) 
described the MRI characteristics evaluated on T1-weighted, 
T2-weighted, and Short tau inversion recovery [STIR] 
sequences, on the axial and coronal images, describing a large 
central necrotic lesion, which determined caliectasis with-
out pelviectasis, localized at the upper and lower renal poles. 
MRI also showed paraaortic lymphadenopathy. The aorta was 
displaced to the right (11). Blitman et al. (21) reported MRI 
findings of three patients. The study was conducted with spin-
echo or gradient-echo (or both) T1-weighted sequences and 
T2-weighted fast spin-echo sequences with and without fat 
suppression in the axial and coronal planes and contrast-en-
hanced T1-weighted or gradient-echo sequences. The results 
were similar to CT in delineating the margins of lesions and to 
evaluate the lymphadenopathy and renal pedicle. MRI allows 
an easier assessment of global extent of disease and seems to 
be superior in detecting intratumoral hemorrhage and hepatic 
metastases. Raman et al. (32) described MRI features of a 
17-year-old male patient with a history of SCT, showing a 
hypointense mass on T2-weighted images with well-defined 
margins and a small heterogeneous internal area on con-
trast-enhanced T1-weighted images on the coronal plane.
Differential Diagnosis
In addition to collecting duct carcinoma, there are other neo-
plastic and non-neoplastic diseases that can mimic the central 
infiltrative RMC activity. Renal lymphoma can show focally 
or diffusely infiltrative pattern of growth (33). In children, the 
location is often multifocal and bilateral (34). Renal involve-
ment occurs also in non-Hodgkin’s lymphoma, and it is vis-
ible only in 5% of patients at initial staging (33). Another 
aggressive tumor with infiltrative pattern is rhabdoid tumor 
of the kidney, which comes with a peritumoral collection in 
75% of cases (35). Mesoblastic nephroma is a benign tumor 
of spindle cells that may present infiltrative features (36). 
Rhabdoid tumor of the kidney and mesoblastic nephroma 
tumor, unlike RMC, occur during early childhood (average 
age of 11 and 3 months, respectively). Wilms’ tumor is the 
most common childhood renal cancer; this tumor is localized 
in the cortex, has an expansive growth, rounded shape and 
well-defined margins (33). Other renal tumors with infiltra-
tive pattern are found in the elderly, for example, transitional 
cell carcinoma and sarcomatoid variants of RCC (33, 36). 
Infectious diseases such as acute bacterial nephritis may 
mimic the infiltrative pattern of RMC on imaging although 
the clinic-laboratory features are very different (21, 33). 
MRI, CT scan, and the anamnesis are important for the char-
acterization of the lesions; CT is fundamental to the staging. 
However, histology must still be performed to confirm the 
diagnosis and to set up a proper treatment plan.
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Management of RMC
A recent study (37) carried out on 52 patients described the 
management and outcomes of RMC patients, featuring pre-
dictors of overall survival. The vast majority of patients pre-
sented with advanced stage of disease, but three patients who 
had local disease, developed tumor recurrence within a few 
months after nephrectomy (median time of 3 months). In this 
study, the overall median survival was 13 months in compar-
ison with the historic 5 months. The prognosis remained low, 
and <20% of patients survived for 24 months. However, in 
well-selected patients who respond to initial chemotherapy, 
or with low volume of metastases, nephrectomy can poten-
tially play an important role also in the metastatic setting, and 
resection of all visible retroperitoneal disease should be the 
target of surgery. The data show that the nephrectomy may 
have a therapeutic benefit upfront or after response to chemo-
therapy. However, the decision to perform nephrectomy is 
influenced by many variables specific to the patient. A thor-
ough patient assessment and a multidisciplinary deliberation 
are needed before a surgical treatment plan. In relation to 
these data, an algorithm has been recommended for RMC 
treatment (Figure 1) (37). The authors recommend the use of 
combined cytotoxic chemotherapy over single agents or tar-
geted therapies, in particular for the palliation of  symptoms. 
They also suggest the next frontier of RMC research is the 
molecular characterization in order to detect biologically 
relevant targets that can be exploited for the development of 
targeted therapies (37). As already mentioned, RMC is cor-
related with the loss of SMARCB1, a tumor suppressor gene 
on chromosome 22 (7, 38, 39). SMARCB1 acts as regulator 
of the remodeling of a repressor of transcription of cyclin D1. 
Therefore, the loss of SMARCB1 leads to an increase of the 
transcription of cyclin D1 in RMC (40). This results in the 
overexpression of Enhancer of zeste homolog 2 (EZH2) (a 
histone methyltransferase). For this reason, EZH2 inhibitors 
such as tazemetostat are used as therapeutic options (7, 41).
Conclusion
RMC is a rare, highly aggressive tumor that occurs mainly in 
African-American adolescent and young adult patients with 
SC hemoglobinopathies. A summary of imaging studies pub-
lished between 1995 and 2016 shows that the highest num-
ber of cases of RMC were evaluated through CT. The most 
frequent CT features were intratumoral necrosis, right renal 
 location, lymphadenopathy, caliectasis, and poorly defined 
margins of the tumor. The features such as areas of necrosis 
and lymph node involvement correlate with the typical his-
tological features of RMC. Few cases have been evaluated 
through ultrasound and MRI, and no case through CEUS. Fur-
ther studies, including different imaging techniques, are war-
ranted to define the characteristics of this aggressive tumor.
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Figure 1. Treatment algorithm by Shah et al. (37). This algorithm suggests the need for a multidisciplinary approach for the effective 
management of renal medullary carcinoma. 
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